This handout is for vascular dementia. Your care team identified this based on: step-wise or fluctuating cognitive decline with prominent executive/processing-speed slowing (informant-corroborated).
Other reasons your team may use this plan: post-stroke / post-tia cognitive impairment on surveillance (multi-infarct or strategic infarct); heavy vascular-risk burden (htn/dm/af/carotid disease/smoking) with new cognitive concern + gait change/early incontinence; mri showing significant infarcts / confluent white-matter hyperintensities / lacunes / microbleeds with temporal/topographic link to cognition.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| reversible_cause_workup | — | — | — | VASCOG — B12, TSH, depression (GDS-15), medication/anticholinergic burble, and structural MRI (NPH/subdural/tumor) excluded or treated before attributing decline to cerebrovascular disease |
| cerebrovascular_imaging_confirmation | — | — | — | NINDS-AIREN — significant CVD on MRI (infarcts, lacunes, confluent white-matter hyperintensities/Fazekas, microbleeds) with a temporal/topographic link to cognition is a diagnostic requirement; assess mixed AD with biomarkers when an amnestic/insidious component coexists |
Plan: Vascular cognitive impairment care ladder — exclude reversible/confirm vascular → AGGRESSIVE secondary vascular prevention (cornerstone) → ChEI/memantine modest/uncertain → depression/PBA/apathy → non-pharm/caregiver/ACP → BPSD non-pharm-first → deprescribe + rehab/falls
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Reinforce and re-titrate secondary prevention at each visit (BP/LDL/HbA1c/anticoagulation/smoking); advance care planning revisited at each transition; driving/finances/capacity reviewed; caregiver respite and support referral; rehab continuity and falls prevention; palliative/end-of-life planning and ChEI/memantine deprescribing decision in advanced (severe) disease (VASCOG)
Guideline: AHA/ASA Scientific Statement — Vascular Contributions to Cognitive Impairment and Dementia (VCID) + 2024-2025 vascular cognitive impairment reviews; NINDS-AIREN and VASCOG diagnostic criteria; DSM-5 vascular neurocognitive disorder; NICE NG97 Dementia; AGS Beers 2023